Balaxi Pharmaceuticals Limited · NSE:BALAXI
Balaxi Pharmaceuticals — Q3 FY2023 Earnings Presentation
23 slides from Balaxi Pharmaceuticals's earnings presentation, Feb 1, 2023
Slide 1: Cover letter to NSE: Investor Presentation Q3 FY2023
February 01, 2023 To, Listing Department, National Stock Exchange of India Limited Exchange Plaza, Plot No C-1, Block G, Bandra Kurla Complex, Bandra (E), Mumbai – 400051 NSE Symbol: BALAXI Dear Sir/Madam, Subject: Investor Presentation Q3 FY 2023 In compliance with Regulation 30 of SEBI (Listing Ob
Slide 2: Balaxi Pharmaceuticals Limited Q3 & 9M FY23 Financial Results
Balaxi Pharmaceuticals Limited Branded IPR-driven Pharma Player in Frontier Markets Q3 & IM FY23 Financial Results
Slide 3: Disclaimer
' Disclaimer Certain statements in this document may be forward-looking statements. Such forward-looking statements are subject to certain risks and uncertainties like regulatory changes, local political or economic developments, technological risks, and many other factors that could cause our actua
Slide 4: Corporate Snapshot, Financial Highlights, Strategic Roadmap
04 Corporate Snapshot 15 Financial Highlights 21 Strategic Roadmap Balaxi
Slide 5: Branded IPR-based pharma company
Branded IPR-based pharma (it — fel company Frontier markets leadership in Latin America and Africa Vast portfolio across diverse therapeutic areas Asset light structure for expansion in semi-regulated markets Balaxi
Slide 6: Supply Chain, Distribution and Transformation
Expansion initiated: Nicaragua, Ecuador, Chile (Latin America) Central African Republic, Zambia (Africa) 766 product registrations in six countries 650 registrations submitted or in the pipeline Establishing EU GMP compliant facilities in Supply Chain Hyderabad Successful process being replicated in
Slide 7: Key Success Factors
Key Success Factors Market Selection Methodology =" Focus on countries with high-potential economic growth framework Identify non-English speaking countries with similar characteristics Low competitive intensity and potential to establish top-2 position On-ground feedback mechanism allows deep under
Slide 8: Transition from Asset Light to Asset Right
Transition from “Asset Light” to “Asset Right” : Marketing and Market Research Product Product Manufacturing Distribution Identification Registration Existing Operations New Manufacturing Unit As a part of its corporate evolution, Balaxi is moving its business model from Asset Light’ to ‘Asset Right
Slide 9: Investment in Manufacturing Facilities
‘Investment in Manufacturing Facilities Sits | e e e e e e e : : Setting up EU GMP compliant pharma manufacturing unit * ° General Oral Solid Dosage (OSD) and Liquid Injection formulations Targeting demand for high quality products in Latin American markets Allows full backward integration of supply
Slide 10: Existing and targeted markets
Portugal Existing Market Dominican e ° Republic @ Targeted Expansion Guatemala _Central 45 @ Product Sourcing Regions El Salvador | —® African b J, Republic \«é. Ecuador Zambia K- I Nee Balaxi Existing/targeted markets have aggregate GDP of S 400 billion and pharma imports of $6 billion ~~~ aiax!
Slide 11: Key Milestones
Key Milestones Started business supplying white labelled products to customers in Africa Diversified supply chain by Products were sourced from sourcing pharma products Set-up central distribution WHO GMP certified plants from WHO GMP certified warehouse in Guatemala, based in India manufacturers in
Slide 12: Group structure and subsidiaries
Balaxi Global DMCC, Dubai (WOS) Balaxi Balaxi Balaxi Balaxi Balaxi Healthcare Healthcare Healthcare Healthcare Healthcare Healthcare Dominica Guatemala Angola LDA EL Salvador Honduras Central African SRL (WOS) S.A (WOS) (WOS) Republic(WOS Existing subsidiary companies Stel eeyd] Balaxi Balaxi iz Pro
Slide 13: Board of Directors
/Ashish Maheshwari /Minoshi Maheshwari /Kunal Bhakta P= Chairman & Managing Director Non-Executive Director Independent Director Founder of the company, first Co-founder, 20 years of Chartered Accountant with 15 years’ generation entrepreneur, rich experience with Balaxi experience, manages First Wa
Slide 14: Strong Leadership Team
Strong Leadership Team Ashish Maheshwari Amol Mantri Chairman & Managing Director CFO Founder of the company, first generation Qualified Chartered Accountant and Certified Public entrepreneur, qualified Chartered Accountant Accountant from USA Commenced business by supplying white labelled Associate
Slide 15: Financial Highlights
ixojog SLHONMHOSIH TWIONVNIS
Slide 16: Management's Comments
Management’s Comments It! “During the quarter, we have strategically focused on our newly launched geographies in the Latin American markets — Guatemala, Honduras and El Salvador. These LATM markets have contributed 40% of our pharmaceuticals revenues and we are confident of increasing this further
Slide 17: Financial Performance — Q3 & 9M FY23
Financial Performance — Q3 & 9M FY23 Particulars(/NR Crore) Q3FY22 ro) 1 Revenue 61.72 sn]: Gross Profit yy SPR Gross Margin % COR VAIS Operating EBITDA 13.55 CEmcy EBITDA Margin % OY 20.5% Profit After Tax any) 34.94 PAT Margin % 19.7% 18.5% Earnings Per Share (INR) a} Byles NOTE: Financial Results
Slide 18: Pharma Product Mix — Q3 FY23
Pharma Product Mix — Q3 FY23 Geographies Products = Angola = Branded = LATM* m= Generics Dosage Forms Therapeutic Areas = Tablets # Antibiotics = Injectables = Analgesic 4 eee = Liquids m Anti-malaria = Capsules = Others = Others 5% Balaxi *LATM — Guatemala, Dominican Republic, Hondurus and El Salva
Slide 19: Quarterly Performance Commentary
‘Quarterly Performance Commentary Revenue = Higher contribution from the pharmaceuticals business led to y-o-y growth of 40.3% in revenues for Q3 FY23 compared to corresponding quarter last year. The share of LATM markets increased to 40% of pharmaceutical revenues, highlighting our ability to quick
Slide 20: Historical Financial Performance
‘Historical Financial Performance Particulars (ir Crore) a Al Revenue 231.33 59.19 Gross Margin % 25.6% Operating EBITDA AEore EBITDA Margin % 19.3% aco ANN) am ED Stoke! PAT Margin % 16.5% Earnings Per Share (INR) eisai) Balaxi
Slide 21: Pharma Product Mix — FY22
Pharma Product Mix — FY22 Geographies Products = Angola = Guatemala = Branded m= Generics = Dominican Republic Therapeutic Areas a Dosage Forms = Tablets # Antibiotics = Injectables = Analgesic 46% = Liquids m Anti-malaria = Capsules = Others = Others Balaxi
Slide 22: Core Strategy: Enter, Expand & Excel
Core Strategy: Enter, Expand & Excel _ Balaxi in 2020: Business Consolidation ee = Presence across Angola, Guatemala and Dominican Republic = Effective and efficient supply chain model consisting of 38 warehouses and a fleet of owned vehicles Balaxi in 2021-22: Expansion into New Geographies = Aim t
Slide 23: Our Offerings and contact details
Our Offerings P Nahi bel tolate Analgesic DyTU lca la Hormone Balaxi Pharmaceuticals Limited Medical Pe Others Witte ran ar Pe stasie Plot No. 409, H.No . 8-2-293, 2nd Floor Maps Towers, Jubilee Hills, Road No:81,Hyderabad. Anti-Malaria Bronchodilator Telangana E rae] 19) Siar Ree Ure CIN: L25191TG1
Balaxi Pharmaceuticals — Q3 FY2023 Earnings Presentation on 6ix